Ranibizumab

[SDL] Ranibizumab (Lucentis) Prefilled Syringe 1.65 mg/0.165 mL

[SDL] Ranibizumab (Lucentis) Injection 2.3 mg/0.23 mL

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

04/01/2022 Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion

The Ministry of Health’s Drug Advisory Committee has recommended:

• Ranibizumab 1.65 mg/0.165 ml pre-filled syringe and 2.3 mg/0.23 ml solution for injection as an alternative to intravitreal bevacizumab for treating adults with visual impairment due to:

  • neovascular (wet) age-related macular degeneration;

  • diabetic macular oedema; and

  • macular oedema secondary to central or branch retinal vein occlusion

in view of an acceptable price proposal from the manufacturer.

Subsidy status

[R] Ranibizumab is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration